UY38455A - Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) - Google Patents

Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)

Info

Publication number
UY38455A
UY38455A UY0001038455A UY38455A UY38455A UY 38455 A UY38455 A UY 38455A UY 0001038455 A UY0001038455 A UY 0001038455A UY 38455 A UY38455 A UY 38455A UY 38455 A UY38455 A UY 38455A
Authority
UY
Uruguay
Prior art keywords
pgds
synthase
inhibiting compounds
hematopoietic prostaglandin
compound
Prior art date
Application number
UY0001038455A
Other languages
English (en)
Inventor
Norman Deaton David
L Larkin Andrew
Christie Schulte
L Smalley Terrence Jr
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY38455A publication Critical patent/UY38455A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (I) en donde Ar1, R21, R23, R24, R25, R26, R27, A, X, Y y W son como se definen en el presente documento. Compuestos inhibidores de prostaglandina D sintasa hematopoyética (H-PGDS) y composiciones farmacéuticas que las comprenden y que son útiles además en el tratamiento de distrofia muscular de Duchenne. La invención también se refiere además a métodos para inhibir la actividad de H-PGDS y tratamiento de trastornos asociados a la misma usando un compuesto de la invención o una composición farmacéutica que comprende un compuesto de la invención.
UY0001038455A 2018-11-08 2019-11-06 Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) UY38455A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862757205P 2018-11-08 2018-11-08

Publications (1)

Publication Number Publication Date
UY38455A true UY38455A (es) 2020-05-29

Family

ID=68542702

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038455A UY38455A (es) 2018-11-08 2019-11-06 Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)

Country Status (10)

Country Link
US (1) US20220009918A1 (es)
EP (1) EP3877384A1 (es)
JP (1) JP2022506850A (es)
CN (1) CN112969698A (es)
AR (1) AR117006A1 (es)
BR (1) BR112021008976A2 (es)
CA (1) CA3117943A1 (es)
TW (1) TW202039479A (es)
UY (1) UY38455A (es)
WO (1) WO2020095215A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183214A1 (en) 2020-06-19 2021-12-23 Motoaki Baba Condensed ring compounds that inhibit h-pgds
CN118401522A (zh) 2021-12-17 2024-07-26 佐藤制药株式会社 抑制h-pgds的氮杂吲哚衍生物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2008121670A1 (en) 2007-03-30 2008-10-09 Sanofi-Aventis Pyrimidine hydrazide compounds as pgds inhibitors
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
CN104710365A (zh) 2008-04-28 2015-06-17 旭化成制药株式会社 苯丙酸衍生物及其用途
CA2722420A1 (en) 2008-05-13 2009-11-19 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin d synthase
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
JP2011524894A (ja) 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
US8536185B2 (en) 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
KR101421785B1 (ko) 2009-03-09 2014-07-22 다이호야쿠힌고교 가부시키가이샤 프로스타글란딘 ｄ 합성 효소를 저해하는 피페라진 화합물
US20120196854A1 (en) 2009-10-06 2012-08-02 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition comprising aromatic heterocyclic compound
SG179199A1 (en) 2009-10-08 2012-04-27 Sanofi Sa Phenyloxadiazole derivatives as pgds inhibitors
ES2601007T3 (es) 2010-01-22 2017-02-13 Taiho Pharmaceutical Co., Ltd. Compuesto de piperazina que presenta un efecto inhibidor de PGDS
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
EP2606893A1 (en) * 2011-12-21 2013-06-26 Sanofi Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application
CA3066979A1 (en) * 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors

Also Published As

Publication number Publication date
AR117006A1 (es) 2021-07-07
EP3877384A1 (en) 2021-09-15
JP2022506850A (ja) 2022-01-17
CN112969698A (zh) 2021-06-15
CA3117943A1 (en) 2020-05-14
WO2020095215A1 (en) 2020-05-14
US20220009918A1 (en) 2022-01-13
TW202039479A (zh) 2020-11-01
BR112021008976A2 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
BR112018007381A2 (pt) compostos úteis como imunomoduladores
BR112017020993A2 (pt) compostos, processo para a síntese de compostos, composição, uso de um composto da fórmula i, método para combater fungos fitopatogênicos, e, semente.
NZ738187A (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY37028A (es) Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds
DOP2017000278A (es) Piridinas sustituidas y método de uso
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
BR112018001400A2 (pt) compostos, processo para a síntese dos compostos, composição, utilização de um composto, método para o combate dos fungos e sementes
SG10201811384TA (en) Mnk inhibitors and methods related thereto
BR112017017349A2 (pt) composto, composição, método para tratar um distúrbio
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
AR104731A1 (es) Benzamidas sustituidas y métodos para utilizarlas
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
CO6321288A2 (es) Sales de compuestos inhibidores de vih
UY38455A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
MX2018015852A (es) Uso de ciertos compuestos para modificar, disminuir o eliminar notas desagradables.